The Patent Finder

Abgenomics Cooperatief U.A.

Also on record
Records under this name other than patents Abgenomics Cooperatief U.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Abgenomics Cooperatief U.A.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,604,800ANTI-PSGL-1 Antibodies
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,897,964ANTI-PSGL-1 Antibodies and Uses Thereof
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,287,871Methods of Inducing Cell Death of an Activated T Cell with ANTI-PSGL-1 Antibodies
Formerly held
Term ended
Term ended May 10, 2025 · High confidence
Term endedTerm ended May 10, 2025High confidence
US 8,663,641Anti-PSGL-1 antibodies
Formerly held
Term ended
Ended no later than May 10, 2025 · USPTO record
Term endedEnded no later than May 10, 2025USPTO record
US 10,030,075Methods of Treating with ANTI-PSGL-1 Antibodies
Formerly held
Term ended
Term ended May 10, 2025 · High confidence
Term endedTerm ended May 10, 2025High confidence
US 9,631,019Methods of Treating GVHD and Transplant Rejection with ANTI-PSGL-1 Antibodies
Formerly held
Lapsed on the fee record
Ended Apr 25, 2025 · High confidence
Lapsed on the fee recordEnded Apr 25, 2025High confidence
US 8,361,472Anti-PSGL-1 antibodies
Formerly held
Lapsed on the fee record
Ended Jan 29, 2025 · USPTO record
Lapsed on the fee recordEnded Jan 29, 2025USPTO record
US 8,828,397ANTI-PSGL-1 Antibodies and Methods of Inducing Cell Death of an Activated T Cell
Formerly held
Lapsed on the fee record
Ended Sep 9, 2022 · High confidence
Lapsed on the fee recordEnded Sep 9, 2022High confidence
US 7,744,888Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
Formerly held
Lapsed on the fee record
Ended Jun 29, 2022 · USPTO record
Lapsed on the fee recordEnded Jun 29, 2022USPTO record
US 8,628,775Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds
Lapsed on the fee record
Ended Jan 14, 2022 · USPTO record
Lapsed on the fee recordEnded Jan 14, 2022USPTO record
10 of 13 patents shown.
Pro members see all 13.
Pro members: see all 13 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited